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Background. The practice of “microdosing”, or the use of repeated, very low doses of 
LSD to improve mood or cognition, has received considerable public attention, but 
empirical studies are lacking.  Controlled studies are needed to investigate both the 
therapeutic potential and the neurobiological underpinnings of this pharmacologic 
treatment.  Methods. The present study was designed to examine the effects of a single 
low dose of LSD (13 micrograms) vs placebo on resting-state functional connectivity and 
cerebral blood flow in healthy young adults.  Twenty men and women, aged 18-35, 
participated in two fMRI scanning sessions in which they received placebo or LSD under 
double-blind conditions.  During each session, the participants completed drug effect 
and mood questionnaires, and physiological measures were recorded. During expected 
peak drug effect, they underwent resting-state BOLD and ASL scans. Cerebral blood 
flow as well as amygdala and thalamic connectivity were analyzed. Results. LSD 
increased amygdala seed-based connectivity with the right angular gyrus, right middle 
frontal gyrus, and the cerebellum, and decreased amygdala connectivity with the left and 
right postcentral gyrus and the superior temporal gyrus. This low dose of LSD had weak 
and variable effects on mood, but its effects on positive mood were positively correlated 
with the increase in amygdala – middle frontal gyrus connectivity strength.  Conclusions. 
These preliminary findings show that a very low dose of LSD, which produces negligible 
subjective changes, alters brain connectivity in limbic circuits.  Additional studies, 
especially with repeated dosing, will reveal whether these neural changes are related to 




 Depressive disorders are among the most prevalent psychiatric conditions.  More than 20% of 
adults in the US meet criteria for a major depressive disorder during their lifetime (1).  Although 
existing antidepressant medications, especially selective serotonin reuptake inhibitors (SSRIs), 
are effective in many patients, these drugs have a number of limitations, including unwanted side 
effects, delay of weeks to take effect and variable effectiveness across individuals. Therefore, 
new medications are needed to manage symptoms of depression. In the last 10 years there have 
been numerous anecdotal reports of the therapeutic effects of very low doses of lysergic acid 
diethylamide (LSD; 10-15 micrograms; g) taken once every 3-4 days (2-5). The doses are about 
1/10th of the dose typically used to produce perceptual distortions. ‘Microdosing’ of LSD is 
widespread and usually occurs without medical supervision (2). Purported benefits include 
enhanced mood, improved cognition, as well as relief from migraine headaches, pre-menstrual 
symptoms and traumatic brain injury (2).  Yet, the effects of such low doses of LSD have only 
recently become the subject of scientific investigation (6) and to our knowledge there have been 
no controlled studies of their purported therapeutic effects. Importantly, the effects of microdoses 
of LSD on brain function are also not known. 
LSD is a serotonin receptor agonist that acts at serotonin receptors, especially 5-HT-2A/C, 
and at higher doses also dopamine (7).  However, the receptor actions of very low doses of LSD 
are less well understood (7, 8). At higher doses, LSD alters connectivity within cortico-striatal-
thalamo-cortical feedback loops, pathways implicated in gating of sensory and sensorimotor 
information, pinpointing the thalamus and its cortical and subcortical connections as important for 
psychedelic-induced effects (9-12).  Relatively little is known about the actions of the drug at very 
low doses.   
One proposed mechanism underlying the potential antidepressive effects of psychedelics 
is alteration in amygdala reactivity, activity, and connectivity (13, 14). Using a higher dose of LSD 
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(100 g vs placebo), Mueller (15) found that LSD reduced reactivity of the amygdala and the 
medial prefrontal cortex during the presentation of fearful faces, a mechanism that could 
contribute to reducing the negative bias experienced by depressed patients (16). Furthermore, 
Preller (11) showed increased global brain connectivity in the amygdala after a similar dose of 
LSD, pinpointing the amygdala as a key target of psychedelic-induced increases in serotonin 2A 
receptor signaling.  
The present study was designed to examine the neural effects of a low dose of LSD (13 
g) on resting state cerebral blood flow (CBF) and connectivity in healthy adults, using fMRI.  The 
13 g dose was selected based on a preliminary dose-ranging study assessing the subjective and 
cardiovascular effects of low acute LSD (17).  This dose produced minimal effects, and thus might 
be suitable for use in a naturalistic setting and for repeated dosing.  Coincidentally, microdose 
users in a large survey identified 13 g as the most effective dose for improving mood and 
cognition (3).  Based on previous studies pinpointing the importance of amygdala and thalamic 
connectivity for the effects of higher doses of LSD and psilocybin (13-15, 18, 19) we specifically 
investigated thalamus- and amygdala seed-based connectivity and its relationship to alterations in 
positive and negative mood. Although the participants in this study were not depressed, we 
reasoned that the pattern of neural activation might shed light on the processes by which the drug 
may have beneficial effects in symptomatic volunteers.  
Methods 
Study Design 
This study used a within-subject, double blind design consisting of two sessions wherein healthy 
young adults received, in random order, 0 (placebo) or 13 g of LSD. Subjective mood states 
and physiological measures were recorded at baseline before drug administration and at 60 min 
intervals after drug administration. During the time of peak drug effect (90 min after drug 
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administration) subjects underwent fMRI scanning. After scanning, participants completed 
behavioral measures complementary to those assessed in the scanner.  
Subjects 
Healthy subjects (N=20, 10 women) aged 18 - 35 were recruited through flyers and online 
advertisements. Screening consisted of a physical examination, electrocardiogram, modified 
Structural Clinical Interview for DSM-V and self-reported health and drug-use history. Inclusion 
criteria were English fluency, right handed, at least a high school education, body mass index of 
18–32 and at least one prior use of a psychedelic drug (e.g., MDMA, LSD, psilocybin, DMT). 
Exclusion criteria were a history of psychosis, severe PTSD or Panic Disorder, past year 
Substance Use Disorder (except nicotine), pregnant or nursing, working night shifts, regular 
medication aside from birth control, adverse reaction to a psychedelic drug or unwillingness to 
use this type of drug again.  
Subjects were required to abstain from drugs and medications for 48 hours before and 24 hours 
after each session, abstain from cannabis 7 days before and 24 hours after each session, and 
abstain from alcohol for 24 hours before and 12 hours after each session. They were permitted 
to consume their normal amounts of caffeine and nicotine up to 3 hours before the scan. 
Subjects were instructed to have a normal night’s sleep and fast for 12 hours before the 
sessions. A granola bar was provided at arrival as a standardized breakfast. To minimize drug-
specific expectancies, subjects were told they might receive a placebo, stimulant, sedative, or 
hallucinogen drug. All subjects provided informed consent prior to beginning the study 
procedures, which were approved by the University of Chicago Institutional Review Board. 
Procedure 
Orientation session 
Subjects attended an orientation session to review the protocol, provide informed consent, 
receive pre-session instructions and practice study tasks and questionnaires.  
Experimental sessions 
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Subjects attended two 5-hour sessions beginning at 9 am, separated by at least 7 days. 
Compliance to drug abstention was verified by urinalysis (CLIAwaived Instant Drug Test Cup, 
San Diego, CA) and breath alcohol testing (Alcosensor III, Intoximeters, St. Louis, MO). Female 
subjects provided urine samples for pregnancy tests, and were tested at any phase of the 
menstrual cycle. After compliance was confirmed, baseline measures of subjective state and 
cardiovascular function were obtained. LSD (13g; tartrate solution in water; Organix, Inc.) or 
placebo (water) was administered sublingually 30 minutes after arrival under double-blind 
conditions in a volume of 0.5 ml. Participants held the solution under the tongue without 
swallowing for 60 seconds, under observation of the research assistant. Subjective and 
cardiovascular measures were taken at 60, 115, 180, and 240 minutes. Scans were conducted 
90 minutes after drug administration, and lasted about 60 min. After the final timepoint at 240 
minutes, subjects completed an end of session questionnaire and were discharged.  
Drug 
The drug was manufactured by Organix, Inc. (MA), and prepared in solution with tartaric acid by 
the University of Chicago Investigational Pharmacy. A dose of 13g was selected to be below 
the threshold for hallucinatory effects (17), and within the range that is used in naturalistic 
settings (4).  
Drug Effect Measures Mood states and subjective drug effects were assessed before and at 
regular intervals after drug administration using the Drug Effects Questionnaire (DEQ) (20, 21), 
the Addiction Research Center Inventory (ARCI) (22, 23), and the Positive and Negative Affect 
Schedule (PANAS) (24). The DEQ consists of five questions assessing subjective drug effects 
using 100mm Visual Analog Scales. Subjects indicate to what extent they feel a drug effect, like 
a drug effect, dislike a drug effect, feel high, or want more of what they received. The ARCI 
consists of 49 "True-False" questions measuring typical drug effects: A (amphetamine-like, 
stimulant effects), BG (benzedrine group, energy and intellectual efficiency), MBG (morphine-
benzedrine group, euphoric effects), LSD (lysergic acid diethylamide, hallucinogen-like effects), 
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and PCAG (pentobarbital-chlorpromazine-alcohol group, sedative effects). The PANAS contains 
20 five-point likert scale items with subscales for positive affect, and negative affect. At the end 
of each session, subjects also completed an end-of-session drug identification questionnaire 
and the 5 Dimensions of Altered States of Consciousness (5D-ASC) questionnaire (25). Blood 
pressure and heart rate were monitored every 30 min using portable blood pressure cuffs 
(Critikon Dinamap Plus; GE Healthcare Technologies, Waukesha, WI, USA). Body temperature 
was recorded using a tympanic thermometer (Braun Thermoscan 5 Digital Ear Thermometer, 
Braun, Kronberg, Germany).   
Imaging 
Imaging was performed using Phillips Achieva Quasar Dual 16 Ch 3T MRI scanner. Echo-planar 
imaging sensitive to the BOLD signal were acquired to measure neural responses during rest 
(repetition time, 2,000 ms; echo time, 29 ms; flip angle, 76°; 35 interleaved 3mm-thick axial slices; 
matrix, 88×88; 2.5×2.5×3.0 mm3 voxels; acceleration factor 2; 180 volumes). Arterial spin labeling 
(ASL) data were acquired to assess for perfusion alterations that might qualify any fMRI changes 
observed. We used a pseudo-continuous sequence (repetition time, 4700 ms, voxel size, 
3.4x3.4x5mm3, field of view, 220x220x145mm3, flip angle, 90°, echo time,13 ms , bolus time,180 0 
ms, TI, 3600 ms) with 35 control-label pairs. A proton density-weighted image (repetition time, 
10000 ms, echo time,13 ms, voxel size, 3.4x3.4x5mm3) was acquired to calibrate CBF 
quantification. A structural scan was acquired using a T1-weighted magnetization-prepared rapid 
gradient echo (MPRAGE) sequence for co-registration and normalization to the Montreal 
Neurological Institute coordinate system.  Head movement was minimized through instructions to 
participants and foam padding around the head.  
Data analysis:  
Peak change-from-baseline values were calculated for each subject on each repeated subjective 
and physiologic measurement. Subjective effects were analyzed using repeated-measures 
analysis of variance (ANOVA) of peak change scores with dose condition as the within-subjects 
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factor. The primary analysis was the comparison of fMRI resting state connectivity after drug and 
placebo.    
fMRI data were analyzed using the  CONN functional connectivity toolbox 18.b 
(http://www.nitrc.org/projects/conn) (26). Preprocessing included functional realignment and 
unwarping, slice-timing correction, co‐registration, structural segmentation and normalization into 
a standard stereotactic space (Montreal Neurological Institute), functional normalization, outlier 
detection (ART-based identification of outlier scans for scrubbing), and smoothing with a 8 mm full 
width at half maximum Gaussian kernel. Denoising included scrubbing with a global signal 
threshold of z > 3 and a composite subject motion threshold of >0.5 mm using ART as 
implemented in CONN. Subjects with more than 20% frames flagged for scrubbing were 
completely excluded from all analyses. All subjects passed these criteria. Further denoising steps 
were linear regression of the six motion parameters and their first derivatives, and the white 
matter and cerebrospinal fluid signals, using individual tissue masks obtained from the T1‐
weighted structural images. The resulting functional images were high‐pass filtered (>0.008 Hz). 
After preprocessing, seed-to-voxel connectivity maps were computed for each participant. 
Previous studies have repeatedly shown that psychedelics alter activity and connectivity in the 
thalamus and the right amygdala in humans (10-14, 18, 27). The right amygdala and the bilateral 
thalamus were therefore selected as seed ROIs derived from the FSL Harvard-Oxford atlas with 
the whole brain as target. The between-conditions contrast LSD>Pla was computed on the 2nd 
level. Results were considered significant after cluster size correction (P < 0.05, FDR) based on a 
cluster‐forming voxel threshold of P < 0.001, uncorrected. Given that the microdosing of LSD has 
anecdotally been reported to have antidepressant effects, we were specifically interested in the 
relationship between LSD-induced alterations in brain connectivity and changes in mood. To 
investigate this relationship, the 1st eigenvariate of significant clusters was extracted for each 
participant and correlated with changes in positive and negative mood (LSD-Pla change score) 
assessed with the PANAS questionnaire directly after scanning.  
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ASL data were preprocessed and CBF maps quantified using FSL’s BASIL toolbox  (28). Briefly, 
this included motion correction and co-registration, CBF maps quantified following Alsop (29), and 
normalization in MNI space. Quality was assessed following each step. For the between-drug 
analysis, CBF maps were globally normalized around 50 ml/100g/min and masked using an 
inclusive grey matter probability mask included with SPM12 set at 80%. A paired t-test was 
conducted on CBF within the right amygdala and bilateral thalamus first to assess change to the 
seed regions, and then on the gray-matter-only CBF maps using SPM12. We evaluated resulting 





Most subjects were Caucasian (Table 1), in their twenties (mean age 25), with some college 
education (mean education 15 years) with some prior drug experience. 
 
Drug response measures 
LSD produced few subjective or physiological effects. Table 2 shows PANAS, ARCI and 
physiological measures before drug administration and immediately after the scan, and DEQ 
values and 5D-ASC values obtained after the scan.  Marginal increases (p<.10) were detected on 
the DEQ ratings of  “feel high” [F(1,19)=3.30, p=0.09], “want more” [F(1,19)=3.69, p=0.07], and 
“like drug” [F(1,19)=3.23, p=0.09], and the drug significantly increased scores on the sedation 
scale PCAG of the ARCI [F(1,19)=8.20, p=0.01].  On physiological measures, LSD 
LSD significantly increased systolic blood pressure [F(1,19)=5.91, p=0.03]. LSD did not 
significantly alter ratings on the 5D-ASC. On placebo sessions, 16 subjects correctly identified the 
substance as placebo, and the remainder (1 each) guessed sedative, stimulant, opioid or 
 10
cannabinoid. On LSD sessions, 8 thought they received placebo, 7 thought they received a 
sedative, and 1 each labelled it stimulant, hallucinogen, opioid, cannabinoid or ‘unsure’.  Men and 
women did not differ on most measures, although women reported experiencing the drug effect 
earlier than men (60 vs 120 min). 
 
Imaging data 
Thalamus seed-based connectivity 
LSD increased thalamus connectivity in two clusters in the cerebellum (peak voxel: x=+26, y=-70, 
z=-32, k=226 and x=-20, y=-72, z=-32, k=189, p<0.05, FDR corrected). No significant changes in 
thalamus connectivity were found in the cortex or subcortical structures. LSD-induced increases in 
thalamic-cerebellar connectivity were not correlated with changes in mood (all p > 0.22).   
Amygdala seed-based connectivity 
LSD increased amygdala seed-based connectivity in the right angular gyrus, right middle frontal 
gyrus and the left cerebellum (p<0.05, FDR corrected, Fig. 1 and Table 3). It decreased 
amygdala seed-based connectivity with the left and right postcentral gyrus and the superior 
temporal gyrus. To investigate the relationship between LSD-induced changes in mood and 
alterations in amygdala connectivity, we conducted an exploratory analysis correlating significant 
changes in connectivity strength with changes in PANAS scores (positive and negative mood) 
across participants. Fig. 1C shows a significant correlation between LSD-induced changes in 
amygdala – mFG connectivity strength and differences in positive mood measured directly after 
scanning in the LSD and Pla conditions (r=0.49, p<0.03). This analysis was also conducted using 
the change in blood pressure as a covariate, but this did not change the results (Supplementary 
Data).  No significant correlations were found for changes in negative mood or with alterations in 
connectivity strength in other brain areas. 
Cerebral Blood Flow 
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Eighteen participants were included in the ASL analysis (two participants were excluded for 
incomplete data collection, and poor quality). No significant differences were found in CBF 




In this study, we tested the effects of a very low “microdose” of LSD (13 g) on resting 
state connectivity in healthy human volunteers. We found that LSD increased amygdala seed-
based connectivity with the right angular gyrus, right middle frontal gyrus, and the cerebellum, and 
decreased amygdala connectivity with the left and right postcentral gyrus and the superior 
temporal gyrus. Although the drug’s effects on mood were small and variable, the increase in 
amygdala – middle frontal gyrus connectivity strength was positively correlated with positive mood 
after the drug. No changes in CBF were recorded. Despite the growing popularity of the practice 
of microdosing in the community and handful of studies investigating the subjective and 
behavioral effects of microdoses of LSD, to our knowledge this the first study to investigate the 
effects of a very low dose of the drug on resting state connectivity and CBF.  
Our results are in line with previous studies investigating changes in amygdala responses 
under the influence of higher doses of LSD and other psychedelics, including psilocybin. The 
amygdala receives inputs from all manner of sensory information-focused areas and prefrontal 
cortex, and the latter is also a target of amygdala afferents, making the interpretation of results 
involving amygdala connectivity a complex process. Nonetheless, our study is consistent with 
prior work showing reduced amygdala system modulation. Using a much higher dose of LSD (100 
g compared to 13 g) Mueller (15) reported dampened amygdala responses to fearful facial 
expressions and Kraehenmann (13) found similar results with the serotonergic drug psilocybin. 
Grimm (18) found that psilocybin not only modulated amygdala activation, but also decreased 
amygdala connectivity to the frontal pole during the viewing of happy faces, and decreased 
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amygdala connectivity with the striatum during the viewing of angry faces. Though Grimm (18) 
investigated task-based connectivity and our study investigated resting-state connectivity, our 
result that LSD decreases connectivity between the amygdala and the superior temporal gyrus, a 
region shown to be involved in the perception of emotions in facial stimuli (30), is of interest in 
light of these previous findings.  Notably, however, the previous studies used substantially higher 
doses of the drugs, and it is of particular interest that we detected these changes in neural 
function at doses of LSD that produce minimal direct subjective or behavioral effects and do not 
alter CBF.  
Amygdala hyperreactivity has been associated with a host of psychiatric disorders 
involving negative processing bias, including major depressive disorder and anxiety disorders (31, 
32). Further, standard antidepressant medications, such as selective serotonin reuptake inhibitors 
(SSRIs) act acutely to dampen, and thereby normalize, disrupted amygdala responses, which 
may be a mechanism underlying their efficacy (33, 34). The extent to which microdoses of LSD or 
other serotonin agonists dampen amygdala activity and connectivity, after either acute or 
repeated dosing, and how these are related to mood symptoms remain an important direction for 
future research.    
Interestingly, we also observed increased connectivity between the amygdala and middle 
frontal gyrus, right angular gyrus, and cerebellum. Beyond dampening amygdala responses to 
negative stimuli, it has been suggested that SSRIs may act by enhancing cortico-limbic 
connectivity in the brain, thereby facilitating appropriate emotion regulation (35). In line with these 
findings, in our study, changes in amygdala-middle frontal gyrus connectivity were significantly 
correlated with changes in positive mood. Furthermore, reduced connectivity between the right 
amygdala and the cerebellum has been reported in depressed patients (36).  These alterations in 
connectivity have been suggested to play a critical role in the pathophysiology of depression given 
that dysfunctions in cerebellar-limbic circuits have been shown to disrupt emotional processing 
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(36, 37). In a future study it will be important to determine whether small doses of LSD normalize 
decreased amygdala-cerebellar connectivity in depressed patients.    
In contrast to LSD-induced changes in amygdala connectivity, we did not find alterations in 
thalamo-cortical connectivity. This is not surprising given that altered information processing in 
thalamo-cortical loops has been suggested to underlie the psychedelic-induced altered state of 
consciousness (9). The “microdose” used in this study did not induce psychedelic symptoms or an 
altered state of consciousness and may therefore not influence these pathways, but rather 
change information processing in emotional networks.  
Our study design had several limitations. First, our study included only healthy volunteers, 
and the effects of the drug on mood or brain function may be different in individuals with 
symptoms of depression or anxiety. Second, we investigated effects of only a single 
administration of LSD, whereas individuals who “microdose” the drug in real-world settings report 
using the drug repeatedly, every 3 or 4 days.  Whether drug produces different effects on brain 
activity or mood after repeated doses remains to be determined.  Another limitation is that we did 
not examine subjects’ responses to behavioral tasks implicated in mood-enhancing effects of 
drugs such as tasks assessing cognitive and emotion processing. Finally, perhaps because of the 
low dose, the effects of the drug were subtle.  For example, we detected correlations between 
mood and connectivity in both the placebo and drug conditions.  The specificity of the effect to the 
drug condition will await further study with additional subjects and repeated dosing.    
In summary, here we report the results of the first study to investigate the effects of a very 
low, “microdose” of LSD on resting state functional connectivity in a sample of healthy human 
volunteers. We describe changes in amygdala connectivity in brain regions that are implicated in  
depression.  It remains to be determined with repeated doses of this low-dose drug result in 
antidepressant effects. These promising findings provide a good basis for pursuing the efficacy of 
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Fig 1. Effect of LSD on Amygdala seed-based connectivity. (A) Unthresholded cortical T-
value map of the effect of LSD>Pla on amygdala seed-based connectivity. Red/orange areas 
indicate regions where participants exhibited stronger amygdala seed-based connectivity in the 
LSD condition, whereas blue/pink areas indicate regions where participants exhibited reduced 
Amygdala seed-based connectivity in the LSD condition compared to the Pla condition. Inlet 
shows the right Amygdala seed (green). Colorbar represents T-values for the contrast LSD>Pla. 
(B) Thresholded (p<0.05, FDR corrected) cortical map showing significant alterations in amygdala 
seed-based connectivity in the LSD>Pla (red areas) and Pla>LSD (blue areas) contrasts. (C) 
Correlation between amygdala – middle frontal gyrus functional connectivity (LSD – Pla) and 
changes in positive mood (LSD – Pla) across subjects (black data points). Grey background 
indicates the 95% confidence interval. Inlet shows the amygdala seed (green) and the middle 
frontal gyrus (red). N = 20. 
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Table 1. Demographic and drug use characteristics of the participants.   
Category Count or Mean ± SD (Range) 
N (male/female) 20 (10/10) 
Age (years) 25 ± 4 (18 - 32) 
Education (years) 15 ± 1 (14 – 18) 
Body Mass Index (kg/m2) 23.0 ± 3.8 (18.6 – 31.1) 
Race  
    Caucasian 12 
    African-American 3 
    Asian 1 
    Other/ More than One Race 4 




    Depression 2.0 ± 1.9 (0 – 6) 
    Anxiety 1.4 ± 2.1 (0 – 8) 
    Stress 3.3 ± 3.4 (0 – 14) 
Current Drug Use (past 
month) 
 
    Caffeine (servings/ day) 1.0 ± 0.9 (0 – 2) 
    Tobacco  
        Smokers/non-smokers 3/17 
        cigarettes/ day, smokers 
only 
1.3 ± 0.6 (1.0 – 2) 
    Alcohol (drinks/ week) 3.6 ± 2.6 (0 – 13) 
    Alcohol (drinking days/ 
week) 
2.7 ± 1.8 (0 – 7) 
    Cannabis (times/ month) 9.5 ± 9.8 (0 – 30) 
Lifetime Drug Use (Non-
Medical; mean number of 
uses for users only) 
 
    Stimulants (13 ever used) 16.6 ± 26.1 (1 - 100) 
    Tranquilizer (9 ever used) 2.9 ± 2.3 (1 – 6) 
    Opiate (7 ever used) 2.3 ± 1.9 (1 – 6) 
    MDMA (17 ever used) 6.1 ± 5.8 (1 – 20) 
    LSD (15 ever used) 6.7 ± 12.3 (1 – 50) 
    Psilocybin (11 ever used) 4.8 ± 5.7 (1 – 20) 







Table 2.  Mean (and sd) values for effects of the drug. Values shown are mean scores 
from before and 180 minutes after drug administration (immediately after the scan). The 
5D-ASC is a retrospective report completed only at the end of the session (240 min). 
The asterisk indicates a difference of p<.05. PANAS Positive and Negative Affect Scale; 
ARCI Addiction Research Center Inventory; DEQ Drug Effects Questionnaire; 5D-ASC 5 
Dimensions of Altered States of Consciousness 
 




13 g LSD 
Pre 
13 g LSD 
Post 
PANAS     
  Positive 25.3 (8.1) 21.7 (9.1) 24.7 (8.0) 21.6 (8.6) 
  Negative 14.5 (1.0) 14.2 (0.4) 14.4 (1.2) 14.2 (0.7) 
ARCI     
  A (amphetamine-like) 2.4 (1.4) 1.9 (1.1) 2.6 (1.3) 2.0 (1.5) 
  MBG (euphoria) 2.5 (1.9) 1.8 (1.5) 2.2 (2.2) 1.8 (1.9) 
  LSD  2.9 (1.0) 3.0 (1.1) 3.3 (1.1) 3.1 (1.1) 
  BG (stimulant-like) 5.7 (1.1) 5.2 (1.6) 6.0 (1.3) 5.4 (1.6) 
  PCAG (sedative-like) 2.7 (1.4) 3.9 (2.1) 2.7 (1.2) 5.1 (2.6)* 
DEQ     
  Feel  3.6 (5.8)  3.5 (5.9) 
  High  1.4 (3.1)  2.0 (2.7) 
  Like  6.7 (14.9)  14.5 (21.0) 
  Dislike  7.7 (16.7)  12.1 (19.1) 
  Want more  6.7 (13.0)  16.3 (21.7) 
5D-ASC     
  Experienced Unity  0.2 (0.7)  0.4 (0.9) 
  Spiritual Experience  0.2 (0.7)  0.2 (0.7) 
  Blissful State  0.8 (2.0)  1.0 (3.2) 
  Insight  0.1 (0.4)  0.5 (1.4) 
  Disembodiment  1.5 (4.5)  0.4 (0.9) 
  Impaired Control and Cognition  0.4 (1.1)  0.3 (1.1) 
  Anxiety  0.4 (1.1)  0.4 (0.9) 
  Complex Imagery  0.4 (1.9)  0.3 (1.1) 
  Elementary Imagery  0.1 (0.2)  0.2 (0.8) 
  Audiovisual Synesthesia  0.1 (0.2)  0.2 (0.7) 
Physiological Measures     
  Systolic Blood Pressure 114.3 (9.6) 108.9 (9.4) 112.7 (11.3) 114.4 (11.7)* 
  Diastolic Blood Pressure 75.5 (12.1) 73.9 (8.7) 75.6 (10.9) 76.9 (10.8) 
  Heart Rate 70.9 (13.3) 66.4 (11.9) 71.0 (14.4) 65.7 (11.5) 








Table 3. Significant changes 
in amygdala seed-based 
connectivity.   
Brain Region Hemisphere x y z k 
LSD>Pla 
Angular Gyrus R 54 -52 40 606 
Middle Frontal Gyrus R 30 18 56 113 
Cerebellum L -34 -62 -34 113 
Pla>LSD 
Postcentral Gyrus L -56 -14 46 218 
Superior Temportal Gyrus R 56 -34 8 168 




































Bershad et al.  Supplement 
1 
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State 
Amygdalar Functional Connectivity 
Supplemental Information 
Supplementary analysis using blood pressure as covariate 
To investigate the influence of systolic blood pressure on functional connectivity, the change 
in systolic blood pressure (post-scan LSD – post scan Placebo) was entered as an additional 
regressor in the model. The change in systolic blood pressure did not correlate with LSD-
induced changes in amygdala or thalamic seed-based connectivity. Including the change in 
systolic blood pressure as a covariate in the thalamic-seed based connectivity analysis did 
not change the results. Including the change in systolic blood pressure as a covariate in the 
amygdala seed-based analysis revealed the results presented in Table S1. This analysis 
revealed a similar pattern of LSD-induced increases and decreases in amygdala connectivity 
as the analysis presented in Fig 1. However, three previously detected clusters did not reach 
significance (Middle Frontal Gyrus, Cerebellum, and Postcentral Gyrus), potentially due to 
reduced statistical power.  
 
Table S1. Significant changes in amygdala seed-based connectivity after including changes 
in systolic blood pressure as covariate.  
Brain Region Hemisphere x y z k 
LSD>Pla 
     
 
Angular Gyrus R 56 -52 40 549 
Pla>LSD 
    
 
Postcentral Gyrus L -60 -14 40 158 
 
Superior Temporal Gyrus R 50 -22 4 166 
 
 
